Iain Foulkes | BiotechTV

top of page

From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

Bright Minds

3 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures

Follow BiotechTV

Sponsors

Sponsor Spotlight